Article
Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
Antimicrobial agents and chemotherapy - 1 Jan 2013
Margeridon-Thermet Severine, Svarovskaia Evguenia S, Babrzadeh Farbod, Martin Ross, Liu Tommy F, Pacold Mary, Reuman Elizabeth C, Holmes Susan P, Borroto-Esoda Katyna, Shafer Robert W
Abstract excerpt
We sought to determine the prevalence of hepatitis B virus (HBV) lamivudine (LAM)-resistant minority variants in subjects who once received LAM but had discontinued it prior to virus sampling. We performed direct PCR Sanger sequencing and ultradeep pyrosequencing (UDPS) of HBV reverse transcriptase (RT) of plasma viruses from 45 LAM-naive subjects and 46 LAM-experienced subjects who had discontinued LAM a median...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.